Study of SPH5030 for HER2-positive advanced colorectal or bile duct cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new medication (SPH5030) for people with advanced colorectal or biliary tract cancer whose tumors have a specific marker called HER2. It may offer a treatment option if previous therapies have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal or biliary tract cancer that has spread or cannot be removed with surgery.
- Your tumor is HER2-positive (high HER2 protein) or has a HER2 gene mutation.
- You have already received standard treatments for your cancer before.
- You are in good physical condition (able to do daily activities, ECOG 0 or 1).
- You have not had anti-HER2 therapy before (like trastuzumab).
- You are not pregnant or breastfeeding and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
This trial tests a new drug, SKB103, for people with HER2-negative breast cancer that has not responded to standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
Hear when a new Biliary Tract or Colorectal Cancer With Her2-positive/Mutated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.